Ventilator-Associated Pneumonia in Immunosuppressed Patients

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Immunology

Background:

• Immunocompromised patients represent a growing segment of critically-ill individuals, facing heightened risks of healthcare-associated infections.
• Ventilator-associated lower respiratory tract infections (VA-LTRI), encompassing ventilator-associated pneumonia (VAP) and tracheobronchitis (VAT), are common in intensive care units (ICUs).

Purpose of the Study:

• To review the specific characteristics of VAP and VAT in immunocompromised patients.
• To discuss recent findings challenging previous beliefs on VAP/VAT incidence and multidrug-resistant (MDR) bacteria in this population.

Main Methods:

• Narrative review of recent literature on VAP and VAT in immunocompromised patients.
• Discussion of diagnostic approaches, including invasive sampling (e.g., bronchoscopy with bronchoalveolar lavage) and molecular tools.
• Examination of epidemiological data, pathogen prevalence (including opportunistic pathogens), and treatment strategies.

Main Results:

• Contrary to prior assumptions, VAP and VAT incidence may be lower in immunocompromised patients compared to non-immunocompromised individuals.
• The association between immunosuppression and MDR bacterial VAP/VAT has been recently questioned.
• Gram-negative bacteria are common, but opportunistic pathogens require specific diagnostic consideration in immunocompromised hosts.

Conclusions:

• Immunocompromised status may not increase VAP/VAT incidence, and the role of MDR bacteria needs re-evaluation.
• Accurate etiological diagnosis is crucial for effective treatment selection in these patients.
• Further research is needed to understand the impact of immunosuppression on VAP/VAT outcomes and optimize empirical antibiotic regimens.